These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3144537)

  • 21. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans.
    Jynge P; Skjetne T; Gribbestad I; Kleinbloesem CH; Hoogkamer HF; Antonsen O; Krane J; Bakøy OE; Furuheim KM; Nilsen OG
    Clin Pharmacol Ther; 1990 Nov; 48(5):481-9. PubMed ID: 2121409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
    Shah PM; Sammann A; Schäfer V; Seczendi M; Knothe H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():209-13. PubMed ID: 3144539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal tolerance of fleroxacin in healthy volunteers.
    Mondorf AW; Buch A; Steinbacher G; Rüdel C; Falkenberg FW
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():179-89. PubMed ID: 2904925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
    Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The penetration of fleroxacin into intra-abdominal abscesses.
    Youngs DJ; Tudor RG; Yoshioka K; Keighley MR
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():115-8. PubMed ID: 3144528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers.
    Hoogkamer JF; Kleinbloesem CH
    Drugs; 1995; 49 Suppl 2():346-8. PubMed ID: 8549357
    [No Abstract]   [Full Text] [Related]  

  • 27. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
    Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
    Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
    Parent M; St-Laurent M; LeBel M
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1249-53. PubMed ID: 2118328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
    Heim-Duthoy K; Peltier G; Awni W
    Antimicrob Agents Chemother; 1990 May; 34(5):922-3. PubMed ID: 2113797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of the penetration of two quinolones into intra-abdominal abscess.
    Tudor RG; Youngs DJ; Yoshioka K; Burdon DW; Keighley MR
    Arch Surg; 1988 Dec; 123(12):1487-90. PubMed ID: 3142444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.
    Rubinstein E; Dautrey S; Farinoti R; St Julien L; Ramon J; Carbon C
    Antimicrob Agents Chemother; 1995 Jan; 39(1):99-102. PubMed ID: 7695338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
    Panneton AC; Bergeron MG; LeBel M
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1515-20. PubMed ID: 3142338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Penetration of ciprofloxacin and fleroxacin into biliary tract.
    Edmiston CE; Suarez EC; Walker AP; Demeure MP; Frantzides CT; Schulte WJ; Wilson SD
    Antimicrob Agents Chemother; 1996 Mar; 40(3):787-91. PubMed ID: 8851613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
    Bauernfeind A; Eberlein E; Hörl G
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():81-9. PubMed ID: 3144553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys.
    Kusajima H; Ishikawa N; Machida M; Uchida H; Irikura T
    Antimicrob Agents Chemother; 1986 Aug; 30(2):304-9. PubMed ID: 3094441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of Ro 23-6240 (AM 833), a new trifluorinated quinolone.
    Weidekamm E; Stöckel K; Dell D
    Chemioterapia; 1987 Jun; 6(2 Suppl):307-8. PubMed ID: 3151346
    [No Abstract]   [Full Text] [Related]  

  • 37. Liquid-chromatographic determination of fleroxacin in serum and urine.
    Awni WM; Maloney JA; Heim-Duthoy KL
    Clin Chem; 1988 Nov; 34(11):2330-2. PubMed ID: 3141086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-performance liquid chromatographic assay and erythrocyte partitioning of fleroxacin, a new fluoroquinolone antibiotic.
    Brunt E; Limberg J; Derendorf H
    J Pharm Biomed Anal; 1990; 8(1):67-71. PubMed ID: 2129330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
    Weidekamm E; Portmann R; Suter K; Partos C; Dell D; Lücker PW
    Antimicrob Agents Chemother; 1987 Dec; 31(12):1909-14. PubMed ID: 3125788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of rifampin on fleroxacin pharmacokinetics.
    Schrenzel J; Dayer P; Leemann T; Weidekamm E; Portmann R; Lew DP
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2132-8. PubMed ID: 8257135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.